Compare Matson Inc (MATX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Zimmer Biomet Holdings Inc — how do they compare? Matson Inc trades at $214.01 (market cap $6.11B), while Zimmer Biomet Holdings Inc trades at $96.11 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 3× Matson Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (0.99%). Which is the better fit depends on your goals.
| MATX | ZBH | |
|---|---|---|
Market Cap | $6.11B | $18.55B |
Sector | Technology | Health |
52-Week High | $223.55 | $107.71 |
52-Week Low | $88.05 | $79.58 |
Enterprise Value | $6.71B | $25.61B |
Dividend Yield | 0.74% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $212.05, up 1.61% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.27 surpassing expectations. Revenue and net income are trending upward, supported by a robust China service and resilient consumer demand. The company's valuation ratios, including a P/E of 13.79 and EV/EBITDA of 7.78, appear reasonable relative to earnings growth.
The outlook for MATX is positive, driven by earnings momentum and a favorable analyst consensus with a $265 price target implying significant upside. Key opportunities include continued trade flow strength and dividend growth, while risks involve Trans-Pacific trade volatility and broader economic pressures. The stock presents a compelling case for growth-oriented investors seeking exposure to niche shipping services.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
